UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549	
------------------------	--

OMB APE	ROVAL
OMB Number:	3235-0287
Estimated average	burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-

Joshua	Reporting Person*					ne and Tick	er or Tra	adina s	Symbol			Dolotionobi	f D	g Person(s) to I	oouer
(Fir		Name and Address of Reporting Person* Hexter Joshua					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP]							10% C	
(Fir						ORIVIP J								Other (below)	specify
(Last) (First) (Middle) 20 MAMILLA AVE.,				3. Date of Earliest Transaction (Month/Day/Year) 11/07/2024									COO &	& CBO	
ALEM, L3	9	414904		4. If Ar	mendm	nent, Date of	f Origina	I Filed	I (Month/Da	y/Year)		ne) Form	i filed by One		son
(Sta	ate) (Z	Zip)										Pers	on		
	Table	I - Nor	n-Deriva	tive S	ecuri	ities Acq	uired,	Dis	osed of	, or Be	nefici	ally Own	ed		
Date			Date	Execution Date, ay/Year) if any		ution Date,	Transaction Disposed Of (D) (Inst Code (Instr. 5)				nd Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price	Transa	ction(s)		(111501. 4)
1 Stock			11/07/2	2024			A		30,000	Α	(1	51	1,833	D	
	Tal												d		
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	on Date,		ction nstr.	of Derivative Securities Acquired (A) or Disposed	Expirati	on Da	te	Amount Securiti Underly Derivati Security	of es ing ve (Instr.	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
	Security (Inst	(State) (Z Table Security (Instr. 3) Stock Tal Conversion or Exercise Price of Derivative (Month/Day/Year)	(State) (Zip) Table I - Nor Security (Instr. 3) Table II - 2. Conversion or Exercise Price of Derivative (Month/Day/Year) Derivative 3. Transaction Date (Month/Day/Year) A. Dee Execution if any (Month/Day/Year)	Table I - Non-Deriva Security (Instr. 3) 2. Transac Date (Month/Da 2. Transac Instruction Date (Month/Da) Table II - Derivati (e.g., pu 2. Conversion or Exercise Price of Derivative (Month/Day/Year) Derivative (Month/Day/Year)	Table I - Non-Derivative S Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 11/07/2024 Table II - Derivative Ser (e.g., puts, ca 2. Conversion or Exercise Price of Derivative (Month/Day/Year) [Conversion of Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year) [Conversion of Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year) [Conversion of Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year) [Conversion of Exercise Price of Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securiti (e.g., puts, calls, w 2. Transaction Date (Instr. 3) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securiti (e.g., puts, calls, w 2. Conversion or Exercise Price of Derivative (Month/Day/Year) Output Transaction Code (Instr. 8) A Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year)	Table I - Non-Derivative Securities Acq Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 11/07/2024 Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, 2. Conversion or Exercise Price of Derivative Security Security 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year)	Table I - Non-Derivative Securities Acquired, Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired, Execution Date, if any (Month/Day/Year) 2. Table II - Derivative Securities Acquired, Execution Date (e.g., puts, calls, warrants, option 2. Conversion or Exercise Price of Derivative Securities Acquired (Month/Day/Year) Security 3. Transaction Code (Instr. 8) 3. Transaction Code (Instr. 8) 5. Number of Execution Date, if any (Month/Day/Year) Code (Instr. 8) 6. Date Expirati (Month/Day/rear) Code (Instr. 8)	Table I - Non-Derivative Securities Acquired, Dispersion of Exercise Price of Derivative Security (Month/Day/Year) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Table II - Derivative Securities Acquired, Dispersion of Exercise Price of Derivative Security 3. Transaction Code (Instr. 8) Table II - Derivative Securities Acquired, Dispersion Date (Month/Day/Year) 3. Transaction Code (Instr. 8) Transaction Code (Instr. 8) 5. Number of Expiration Date (A) or Disposed of (D) Code (Instr. 8)	Table I - Non-Derivative Securities Acquired, Disposed of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date Execution Date, if any (Month/Day/Year) Code (Instr. 8) Code V Amount Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertible) 2. Conversion or Exercise Price of Derivative Security Security Security 3. Transaction Code (Instr. 8) Code V Amount 4. Transaction Code (Instr. 8) S. Number of Date (Month/Day/Year) Securities Acquired (A) or Disposed of (D) Security Securities Acquired (A) or Disposed of (D)	Table I - Non-Derivative Securities Acquired, Disposed of, or Be Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Code (Instr. 8) Code V Amount (A) or Disposed of, Or Bender (Conversion or Exercise Price of Derivative Security 3. Transaction Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Bender (e.g., puts, calls, warrants, options, convertible security 3. Transaction Date (Month/Day/Year) Transaction Code (Instr. 8) 5. Number of Date (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title a Amount Security Underly Derivative Security	Conversion Or Exercise Price of Derivative Security (Instr. 3) Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a securities Acquired (Instr. 8) Securit	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Own Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and Securities Acquired (Month/Day/Year) 5. Number of Derivative Securities Acquired (Month/Day/Year) 5. Number of Derivative Securities Underlying Derivative Securities Nacquired (A) or Disposed of (D) (Instr. 3, 4 and Securities (Instr. 3) 5. Number of Derivative Securities (Month/Day/Year) 5. Number of Derivative	Security (Instr. 3) Securities (Instruction Date (Instr. 4) Securities (Instruction Date (Instr. 5) Securities (Instr. 4) Securities (Instr. 5) Se	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (State) (Xip) Form filed by One Reporting Pers Form filed by More than One Reported Form filed by More than One Reporting Pers Form filed by More than One Reporting Person 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) Code V Amount (A) or Price (D) or Indirect (D) or In

Date Exercisable

Expiration Date

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

Code

/s/ Joshua Hexter

11/08/2024

** Signature of Reporting Person

or Number

of Shares

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

|--|

OMB APPROVAL

OMB Number:	3235-028
Estimated average bure	den
hours per response:	0.9

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kidron Miriam					<u>OR</u>	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP]								(Chec	k all app Direc	,		rson(s) to Is 10% Ov Other (s	vner		
(Last) (First) (Middle) 20 MAMILLA AVE.,						3. Date of Earliest Transaction (Month/Day/Year) 11/07/2024								below) Chief Scientific Officer							
(Street) JERUSA (City)	LEM, L3		414904 Zip)		4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indi Line)	,				on					
		Table	I - Nor	n-Deriva	tive \$	Secu	rities	s Acq	uired,	Dis	posed of	, or E	Benef	icially	/ Own	ed					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (and Disposed Of (D) (Instr. 3) 5)		5, 4 and Securitie Beneficia		ties For cially (D) Following (I) (r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)								
									Code	v	Amount	(A) (D)	or P	rice	Transa (Instr. 3	ction(s) 3 and 4)			(111511. 4)		
Common	Stock			11/07/	2024				A		30,000	A	\	(1)	79	3,666		D			
		Tal									osed of, onvertib				Owne	d 					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/l		Code (In				of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Da		Expiration Date A Month/Day/Year) S U		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of erivative security security securities Beneficial Owned Following Reported Transactic (Instr. 4)		ove es ially Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amou or Numb of Share	er							

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

/s/ Miriam Kidron

11/08/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	7110		11711	OL.	
Nachington	$D \subset 2$	0549			

Washington, D.C. 20549	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	9: 0.5

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-
1(c). See Instruction 10.

1(c). Se	ee Instruction 1	0.																		
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC.								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>KIDRON NADAV</u>						ORAMED PHARMACEUTICALS INC. [ORMP]												Owner		
						OKWI J									Officer (give title Other (specify below)					
(Last) (First) (Middle) 20 MAMILLA AVE						3. Date of Earliest Transaction (Month/Day/Year)								President and CEO						
20 IVIAIVIILLA AV E.,					11/0	11/07/2024														
(Street)					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
JERUSA	LEM, L3	9	41490)4	1									Form filed by One Reporting Person						
														Form filed by More than One Reporting Person						
(City)	(St	ate) (Z	Zip)																	
ı		Table	I - No	on-Deriva	tive	Secui	rities	Acc	quirec	l, Dis	sposed of	, or B	enefici	ally Own	ed					
Date				2. Transacti Date (Month/Day	Execution Dat			ate,	3. Transa Code (8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Beneficia Owned F	s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Ownership		
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			Instr. 4)		
Common	Stock			11/07/20	024	24			A		45,000	A	(1)	1,826	1,826,098		D			
															By wholly-					
Common	Stock												126,	000			owned corporation			
						ve Securities Acquired, Disposed of, or Benefic												Corporation		
l		Tal	ble II								osed of, convertib				d					
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deem erivative Conversion Date Execution or Exercise (Month/Day/Year) if any			ition Date, Transac				6. Date Exer Expiration I (Month/Day)		ate	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivati Securiti Benefic Owned Followin Reporte Transac	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		ip of Indirect Beneficial Ownership (Instr. 4)			
						v	(A)	(D)	Date) Exercisa		Expiration Date Title		Amount or Number of Shares							

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

/s/ Nadav Kidron

11/08/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	
------------------------	--

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-

1(c). S	ee Instruction	10.																
1. Name and Address of Reporting Person* Gabay Avraham					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC.									eck all app	,		. ,	
——————————————————————————————————————					ORMP]									Direct Office		10% Ov Other (s		
(Last) (First) (Middle) 20 MAMILLA AVE.,				3. Date of Earliest Transaction (Month/Day/Year) 11/07/2024									Delow	thief Fina	ncial (below) Officer		
(Street) JERUSALEM, L3 9414904				4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(City)			Zip)												filed by Mo	-	-	
		Table	I - Non	n-Deriva	tive S	ecui	rities Acq	uired,	Disp	osed of	, or	Ben	eficia	illy Own	ed			
Date					Date E Month/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					Benefic Owned	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A (D	A) or D)	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common	Stock			11/07/	2024		A		30,000	A		(1)	17	170,040		D		
		Tal					ties Acqu varrants,								t			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any		on Date,	Transaction Code (Instr. 8) Securit Acquir (A) or Dispos of (D)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y C F D o (I	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershij (Instr. 4)	

Date Exercisable

Expiration Date

Explanation of Responses:

1. Represents a grant of 30,000 Restricted Stock Units ("RSUs") that will vest on November 7, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

(A)

/s/ Avraham Gabay 11/08/2024

Amount or Number

of Shares

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)